Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

Abstract The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatellite-high/DNA mismatch repair-deficient biomarker. This is the first example of a t...

Full description

Bibliographic Details
Main Authors: Michael M. Boyiadzis, John M. Kirkwood, John L. Marshall, Colin C. Pritchard, Nilofer S. Azad, James L. Gulley
Format: Article
Language:English
Published: BMJ Publishing Group 2018-05-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
DNA mismatch repair
Microsatellite instability
Pembrolizumab
Biomarker
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s40425-018-0342-x

Internet

http://link.springer.com/article/10.1186/s40425-018-0342-x

Similar Items